TEST:

OncoReveal™ Dx Lung and Colon Cancer Assay (O/RDx-LCCA)

oRDx-LCCA is a highly accurate NGSbased assay for the detection >3,600 mutations across 22 genes in multiple tumor types.

"Pillar Biosciences...announced the presentation of clinical validation data for the FDA-PMA1 approved oncoReveal Dx Lung & Colon Cancer Assay, along with three additional posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting...Results demonstrate that oncoReveal Dx detects clinically significant variants (KRAS G12/G13, EGFR L858 and exon 19 deletion, and BRAF V600E) from as low as 10ng of DNA input with LoD between 1.5% and 2.6% (VAF, Variant Allele Frequency)."

oRDx-LCCA is a highly accurate FDA approved IVD assay and PiVAT is a powerful FDA approved software tool for the detection of clinically relevant KRAS variants in CRC and EGFR variants in NSCLC and determination of approved therapy.

"In the second part of Pillar’s corporate workshop, Dr. Lynn Fink of Xing Cancer Care will speak about their validation and use of the ONCO/Reveal HRD Panel."

"O/RDx-LCCA is a highly accurate CE IVD approved assay for the detection of clinically relevant KRAS variants in CRC and EGFR variants in NSCLC"